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Abstract: Tumor Necrosis Factor- (TNF-), a secreted cytokine, plays an important role in inflammatory diseases and 
immune disorders, and is a potential target for drug development. The traditional assays for detecting TNF-, enzyme 
linked immunosorbent assay (ELISA) and radioimmunoassay, are not suitable for the large size compound screens. Both 
assays suffer from a complicated protocol, multiple plate wash steps and/or excessive radioactive waste. A simple and 
quick measurement of TNF- production in a cell based assay is needed for high throughput screening to identify the lead 
compounds from the compound library. We have developed and optimized two homogeneous TNF- assays using the 
HTRF (homogeneous time resolved fluorescence) and AlphaLISA assay formats. We have validated the HTRF based 
TNF- assay in a 1536-well plate format by screening a library of 1280 pharmacologically active compounds. The active 
compounds identified from the screen were confirmed in the AlphaLISA TNF- assay using a bead-based technology. 
These compounds were also confirmed in a traditional ELISA assay. From this study, several beta adrenergic agonists 
have been identified as TNF- inhibitors. We also identified several novel inhibitors of TNF-, such as BTO-1, CCG-
2046, ellipticine, and PD 169316. The results demonstrated that both homogeneous TNF- assays are robust and suitable 
for high throughput screening. 
Keywords: AlphaLISA technology, HTRF technology, inhibition of TNF- production, qHTS, TNF-, 1536-well plate. 
INTRODUCTION  
  There are three members in the family of tumor necrosis 
factors (TNF): TNF-, TNF- (also called lymphotoxin , 
LT-) and LT- [1]. TNF-, a 17 kDa cytokine, is mainly 
secreted by activated macrophages [2] and monocytes [3] in 
response to several inflammatory and immunological stim-
uli. For example, during bacterial infection, lipopolysaccha-
ride (LPS), a component of gram-negative bacterial cell wall, 
induces the release of TNF-, one of numerous endogenous 
cytokines [4]. TNF- plays an essential role in the immune 
system [4-6]; where it is involved in inflammation, tumor 
necrosis, inhibition of viral replication, and in some cases 
programmed cell death. At the cellular level, TNF- regu-
lates multiple signaling pathways, such as apoptosis and NF-
kB activation, through its cell surface receptors, TNF- re-
ceptor type 1 (TNFR1) and TNF- receptor type II (TNFR2) 
[7]. For example, TNF- binding to TNFR1 initiates a series 
of cellular events, such as activation of a group of kinases 
which includes mitogen-activated protein kinase kinases 
(MEKKs), mitogen-activated protein kinases (MAPKs), and 
inhibitor of nuclear factor-B kinase kinases (IKKs). Activa-
tion of these kinases leads to the regulation of down stream 
target gene expression, such as cytokines, chemokines and 
proteases [7].  
  Overproduction of inflammatory cytokines, such as TNF-
, has been linked to inflammatory disorders such as Crohn’s  
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disease (CD) and inflammatory bowel disease [8, 9]. Cur-
rently, the most effective treatments approved by the FDA 
for CD are the protein-based TNF- antagonists such as in-
fliximab and adalimumab [9]. Natural products have also 
been investigated, due to several potential side effects of 
these protein-based TNF- inhibitors. Several small mole-
cule natural products including etanercept, reservatrol, cu-
ricumin, and lycorine have been found to reduce TNF- lev-
els, and may be an alternative approach to the development 
of small molecule inhibitors to suppress TNF- signaling [7].  
  In order to screen large amounts of compounds to iden-
tify new inhibitors that block TNF- secretion, a fast and 
simple assay format is needed. Currently, the most common 
available methods for TNF- measurement are ELISA (En-
zyme Linked ImmunoSorbent Assay) and radioisotope la-
beled immune assay. However, these assays have compli-
cated assay protocols including several wash steps with long 
incubations and generation of a large amount of radioactive 
waste, which limits the screen throughput. In this study we 
have developed two homogenous TNF- assays using 
HTRF-based and AlphaLISA-based assay formats. Both 
assays have been miniaturized into a 1536-well plate format 
and validated in a quantitative high throughput screening 
(qHTS) platform [10]. 
MATERIALS AND METHODS 
Cell Line and Culture Conditions 
  The THP-1 (Human Acute Monocytic Leukemia) cell 
line was obtained from American Type Culture Collection 
(ATCC TIB-202; Manassas, VA). THP-1 cells, which origi-22    Current Chemical Genomics, 2011, Volume 5  Leister et al. 
nate from the blood of a boy with acute monocytic leukemia 
[11], were cultured in RPMI 1640 (ATCC) medium supple-
mented with 10% fetal bovine serum (FBS, Thermo Scien-
tific HyClone, Logan, UT, USA), 50 U/ml penicillin and 50 
μg/ml streptomycin (Invitrogen, CA), and 0.05 mM 2-
Mercaptoethanol (Invitrogen). The cell cultures were main-
tained in a 37°C incubator with 5% CO2 and under a humidi-
fied atmosphere. 
Chemical Compounds  
  A library of pharmacologically active compounds (LO-
PAC), containing 1280 compounds with known pharmacol-
ogical actives, was purchased from Sigma (St. Louis, MO). 
Lipopolysaccharides (LPS), dobutamine hydrochloride, el-
lipticine, histamine dihydrochloride, Bay 11-7085, PD 
169316, BTO-1, and IRAK-1/4 Inhibitor I were obtained 
from Sigma. CCG-2046 was purchased from Tocris Bio-
science (Ellisville, MO). 
HTRF-Based TNF- Assay and qHTS  
  The secreted Human TNF- in the cell culture medium of 
THP-1 cells was measured using an assay kit (Cisbio Bioas-
says, Bedford, MA, USA) based on the HTRF format (Fig. 
1). HTRF [12, 13] combines standard FRET (fluorescence 
resonance energy transfer) technology with time-resolved 
fluorescent measurement, which could eliminate short-lived 
background fluorescence. For the assay optimization, THP-1 
cells suspended in culture medium were dispensed at 2000, 
3000 or 4000 cells/5 L/well in 1536-well white solid plates 
(Greiner Bio-One North America, Monroe, NC) using a Bio-
raptr dispensing system (Aurora Discovery, CA, USA). 
Twenty-three nL of LPS, a known TNF- inducer [4], at 
final  concentration ranging from 0.56 ng/ml to 9.2 g/ml 
was transferred to the assay plate by a pintool work station 
(Kalypsys, San Diego, CA). The assay plates were incubated 
at 37°C for 5, 17, or 24 hr, followed by addition of 5 L 
mixture of cryptate labeled and XL665 labeled anti-TNF 
antibodies. After the assay plates were incubated at room 
temperature (RT) for 3 hr, the plates were measured by a 
plate reader in a HTRF detection mode. 
 The  TNF- antagonist screening was described in Fig. 2. 
Briefly, THP-1 cells were dispensed at 3000 cells/4 L/well 
in 1536-well white solid bottom plates, followed by an addi-
tion of 23 nL compound in DMSO soultion from LOPAC 
library or DMSO only with a pintool work station (Kalyp-
sys). Each compound was screened at 7 final concentrations 
ranging from 2.9 nM to 46 M, as the DMSO solutions of 
compound library was titrated at 1:5 ratio. After a 5 to 10 
min incubation, 1 L LPS in assay medium at 5 g/mL LPS 
(final concentration of 1 g/mL) was dispensed into the as-
say plates by a Bioraptr dispensing system. The assay plates 
were incubated for 17 hours at 37°C, followed by addition of 
5 L mixtures of cryptate labeled anti-TNF antibody and 
XL665-labeled TNF- antibody. After the assay plates were 
incubated at RT for 3 hr, the dual fluorescence emissions of 
615 and 665 nm with a 320 nm excitation were measured 
using an Envision plate reader (Perkin Elmer, Shelton, CT). 
The results were expressed as the ratio of 665nm/615nm 
emissions. The signal (ratio) was reciprocally reduced with 
the increase of secreted TNF- in the medium. There was no 
detergent in the assay buffer for this TNF- assay. Thus, the 
cells in each well were kept intact and only the secreted 
TNF- was detected.  
Hit Compounds 
  After primary screening, the selected actives were 
cherry-picked and re-tested for the inhibition of LPS induced 
TNF- production in 24 point titrations with final concentra-
tion ranging from 6 pM to 46 M in a HTRF human TNF- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Principle of HTRF-based TNF- assay. The assay was designed using time resolved fluorescence resonance energy transfer (TR-
FRET) technology. In this assay, two anti-TNF- antibodies are labeled with europium Cryptate and XL665, respectively. In the absence of 
TNF-, there is no FRET between these two labeled antibodies, which produces fluorescent signal at 615 nm (Fig. 1A). When TNF- is pre-
sent, these two labeled antibodies are brought into close proximity of each other, which allows FRET to occur between the two fluorophores, 
europium Cryptate and XL665 (Fig. 1B). This reaction produces a fluorescent signal at 665 nm. The increase of FRET levels is proportional 
to the concentrations of TNF-.  
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assay using the same protocol as described above except that 
the 24 point titrations were laid out within one 1536-well 
plate. 
  Furthermore, the powder samples of eight  compounds 
confirmed from the above assay were re-ordered from com-
mercial sources and tested in the same assay protocol as de-
scribed above.  
AlphaLISA-Based TNF- Assay  
  An alternative homogenous TNF- assay based on 
PerkinElmer AlphaLISA [14, 15] assay format (Fig. 3) was 
used to confirm the active compounds identified from the 
primary screen of HTRF based assay. The cell seeding, 
compound addition and LPS treatment were  the same as 
described above except the detection of TNF- was using an 
AlphaLISA-based assay. Briefly, 1.5 L of the mixture con-
taining acceptor beads conjugated with anti-TNF- antibody 
was added into each well after the assay plates were incu-
bated at 37°C for 17 hr. The assay plates were incubated in 
the dark at RT for 1 hr, followed by the addition of 1.5 L of 
donor bead coated with streptavidin which captures the bi-
otinylated anti-TNF- antibody. After the assay plates were 
incubated in the dark at RT for another 1 hr, the assay plates 
were read in the AlphaScreen mode on the Envision plate 
reader (Perkin Elmer). 
Cell Viability Assay 
  Cell viability was measured using a luciferase-coupled 
ATP quantitation assay (CellTiter-Glo
®, Promega, Madison, 
WI). THP-1 were dispensed at 3000 cells/well in 1536-well 
white/solid bottom assay plates using a FRD, followed by 
addition of compounds via a pintool work station. The assay 
plates were incubated for 17 hr at 37°C. At the end of the 
incubation period, 5 μL of CellTiter-Glo
® reagent was 
added, plates were incubated at RT for 30 minutes, and lu-
minescence intensity determined in the luminescence mode 
using a ViewLux plate reader (PerkinElmer).  
Measurement of TNF- Using ELISA Method 
  THP-1 cells were plated at the cell density of 4.8 x 10
4 in 
200 l culture medium per well in a 96-well plate. Twenty-
five  L culture medium with or without compound was 
added into each well, followed by addition of LPS at 1 g/ml 
final concentration in culture. The final concentrations of the 
compounds in the wells ranged from 1.6 nM to 30 M. After 
17 hr treatment at 37°C, the cell culture supernatants were 
removed and measured for human TNF- using human TNF-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). qHTS protocols for HTRF-based and AlphaLISA-based TNF- assays. THP-1 cells were dispensed at 3000 cells/well in 1536-well 
plates. After 23 nL compound or DMSO only was added into the assay plates, 1 L assay medium with or without 5 g/mL LPS (final con-
centration, 1 g/mL) was added into the assay plates. The assay plates were incubated for 17 hours at 37°C. For HTRF-based assay format, 5 
L anti-TNF cryptate/XL665 mixtures were added into the assay plates. After the assay plates were incubated at RT for 3 hr, fluorescence 
intensity (320 nm excitation, 615 and 665 nm emission) was measured using an Envision plate reader (Perkin Elmer). For AlphaLISA-based 
assay format, 1.5 L of the mixture containing acceptor beads and anti-TNF- antibody was added into each well. The assay plates were 
incubated in the dark at RT for 1 hr, followed by the addition of 1.5 L of donor bead. After the assay plates were incubated in the dark at 
RT for another 0.5 to 1 hr, the assay plates were read in the AlphaScreen mode on the Envision plate reader (Perkin Elmer). 
(1)   Dispense 3000 cells/4µL/well into 1536-well plates 
(3)   Add 1µL of LPS (1µg/ml, final) into assay plates 
(2)   Transfer 23nL of compound or DMSO into assay plates 
(4)   Incubate plates at 37ºC for 17 hr 
(5)   Add 5µL ant-TNFα cryptate/XL665 
(6)   Incubate plates at RT for 1 hr 
(7)   Read plates in EnVision plate reader 
HTRF, Cisbio  AlphaLISA, Perkin Elmer 
(5)   Add 1.5µL acceptor bead/ ant-TNFα mixture 
(6)   Incubate plates at RT for 3 hr 
(7)   Add 1.5µL donor bead 
(8)   Incubate plates at RT for 0.5 – 1 hr 
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 immunoassay kit (R&D Systems, Minneapolis, MN). 
Briefly, 200 uL of sample or known standard (0-1000 pg/ml) 
was added to wells of a microplate which was pre-coated 
with a monoclonal antibody specific for TNF- and incu-
bated at RT for 2 hr. After washing away any unbound sub-
stances, an enzyme-linked polyclonal anti-TNF- antibody 
was added and the plate incubated for 1 hr at RT. Following 
four washes, a substrate solution was added and incubated 
for 15-20 min, followed by the addition of a stop solution. 
The optical density of each well was determined at 450 nm 
with 570 nm as a reference filter using an EnVision plate 
reader.  
  The raw data was normalized to LPS (1 g/mL, 100%) 
and assay medium with 0.1% DMSO (basal, 0%). The inhi-
bition curves for each compound were analyzed using the 
non-linear regression analysis program in GraphPad Prism 
(Soft-ware).  
qHTS Data Analysis 
  Data normalization, correction and fitting of concentra-
tion response curves were performed as previously described 
[16]. Briefly, raw results for each titration point was first 
normalized relative to the LPS control (1 g/ml, 0%) and 
DMSO only wells (basal, -100%), and then corrected by 
applying a pattern correction algorithm using compound-free 
control plates (DMSO plates) to minimize the dispense and 
reading errors. Concentration-response titration points for 
each compound were fitted to the Hill equation yielding con-
centrations of half-maximal inhibition (IC50) and maximal 
response (efficacy) values. Concentration response curves 
were classified into four major classes using the set of crite-
ria listed in previous studies [17]. 
  Compounds which showed inhibition in both the rati-
ometric and 665 nm readings, and had potency less than 5 
M and efficacy greater than 50% in the ratiometric reading 
were considered as active in the HTRF human TNF- assay. 
These compounds were further prioritized based on their 
activity in the cell viability assay after 17 h compound treat-
ment. Twenty-six active compounds that were not apparently 
cytotoxic (6 times more potent in the HTRF human TNF- 
assay than that in the cell viability assay) were cherry-picked 
for confirmation and follow up studies.  
RESULTS  
Assay Optimization and Miniaturization of HTRF-Based 
TNF- Assay  
  We have optimized and validated a homogenous HTRF-
based TNF- assay in a 1536-well plate format that can be 
used to screen compounds to identify potential TNF- in-
hibitors (Fig. 1). LPS, a known TNF- stimulator, induced 
TNF- production in a concentration-dependent manner after 
17 hr incubation with the THP-1 cells (Fig. 4A). The EC50 of 
LPS was 0.84 g/ml, and the maximum induction of TNF- 
production by LPS was more than 8-fold of the basal level.  
  To determine the optimal incubation time, the cells were 
incubated with concentration titrations of LPS for 5 to 24 hr. 
The EC50s of LPS are 2.52, 0.84 and 2.22 g/ml for 5, 17 
and 24 hr incubation, respectively. The signal-to-basal ratio 
under maximum LPS treatment was highest after 17 hr of 
incubation (8.7-fold), followed by 24 hr incubation (4.9-fold) 
and 5 hr incubation (4.6-fold). Therefore, the 17 hr incuba-
tion of LPS with THP-1 cells was chosen for compound 
treatment for the rest of the study (Fig. 4A).  
  The optimal cell density in a 1536-well plate format was 
determined by varying cell numbers in a homogenous HTRF 
TNF- assay. The EC50s of LPS were 0.70, 0.74 and 0.84 
g/ml for 2000, 3000, and 4000 cells per well, respectively. 
The signal-to-basal ratios under maximum LPS treatment 
after 17 hr incubation were 6.9-, 9.1-, and 9.1-fold for the 
cell density at 2000, 3000, and 4000 cells per well, respec-
tively (Fig. 4B). 3000 and 4000 cells/well yielded slightly 
higher signal-to-basal ratios than 2000 cells/well. Thus, 3000 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Principle of AlphaLISA-based TNF- assay. The Alpha donor bead (blue color) is coated with streptavidin which captures the bi-
otinylated anti-TNF- antibody. The acceptor bead (orange color) is coated with TNF- specific antibody. When TNF- is present, the two 
coated beads are brought into proximity through binding to TNF-. After excitation by laser at 680 nm, the singlet oxygen released by alpha 
donor bead travels to the nearby acceptor bead where it causes acceptor bead to emit fluorescence at 615 nm. The increase of AlphaLISA 
signal is proportional to the concentrations of TNF-.  
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cells/well was chosen to prevent possible overcrowding of 
cells at the higher density of 4000 cells/well.  
  Thus, this assay is simple and robust and is suitable for 
high throughput screening of compound libraries. It has been 
miniaturized into the 1536-well plate format to increase 
screen throughput and to reduce reagents consumption.  
LOPAC Library Screen Using qHTS  
  The LOPAC library containing 1280 compounds with 
known pharmacological activities was screened to evaluate 
the HTRF TNF- assay. The inhibitory effect of the com-
pounds on TNF- production was measured in the presence 
of 1 g/ml (EC80 value) of LPS in a quantitative high 
throughput screening (qHTS) platform. The average signal-
to-basal ratio for LPS was 8.4 ± 1.3 (mean ± SD) and the 
average Z’ factor was 0.8 ± 0.06 for this primary screen, 
indicating a robust assay for compound library screen.  
  The compound potencies and efficacies were calculated 
from the primary results obtained from this LOPAC library 
screen using the HTRF-based  TNF- assay as it was de-
scribed in the Methods section. The primary hits were se-
lected as these compounds had IC50 values less than 1 M 
and inhibitory efficacy greater than 50% of control response 
in the HTRF TNF- assay while they were inactive or 6 fold 
less potent in the cell viability assay. A total of 26 com-
pounds met these criteria as potential inhibitors of TNF- 
production and they were cherry-picked for the further fol-
low-up studies. 
Confirmation of TNF- Inhibitors Using an AlphaLISA-
Based TNF- Assay 
  The 26 cherry-picked compounds were re-tested in the 
HTRF-based TNF- assay. The inhibitory activity of LPS-
induced TNF- production was confirmed in 25 of 26 se-
lected compounds (Table 1) and the confirmation rate of was 
96%. To eliminate the potential false positives due to the 
detection method used in the above assay, these 25 com-
pounds were further evaluated in another homogeneous 
TNF- assay that applied the AlphaLISA assay method (Fig. 
3). The assay signal in the AlphaLISA assay was measured 
in the AlphaScreen mode instead of the HTRF detection 
mode in the HTRF TNF- assay. The activities of all 25 
compounds were confirmed in the AlphaLISA-based TNF- 
assay with a concordance rate of 100%. The potency ranking 
of the compounds in these two assays was very similar. The 
IC50 values of these compounds in the two assay formats 
correlated well with an R
2 of 0.93. Formoterol was the most 
potent compound among these confirmed compounds. Its 
IC50 values were 4 nM and 6 nM in both the HTRF-based 
assay and the AlphaLISA-based TNF- assay, respectively 
(Table 1). Among these 25 compounds, 15 were known beta 
adrenergic receptor agonists including formoterol, fenoterol, 
alpha-methynorepinephrine, epinephrine, norepinephrine and 
isoproterenol. The IC50 values of these beta adrenergic recep-
tor agonists ranged from 4 nM (formoterol) to 3.5 M (ri-
todrine). PD169316 (0.12 M), a p38 MAPK kinase inhibi-
tor, and NFB pathway inhibitors, Bay 11-7082 (1.2 M) 
and Bay 11-7085 (0.88 M), were also found active in the 
inhibition of LPS induced TNF- production. The IC50 val-
ues of these 25 compounds from both the HTRF-based TNF-
 assay and the AlphaLISA-based TNF- assay are listed in 
Table 1. These data suggest that the two assays, the HTRF 
TNF- assay and AlphaLISA TNF- assay, are equally sen-
sitive to inhibitors. These homogenous assays can be easily 
scaled up to screen a large compound library quickly and 
efficiently. They can also be used to counter-screen each 
other to eliminate the detection-related false positive com-
pounds.  
Comparison of the Homogenous HTRF-Based Assay with 
the Traditional ELISA-Based Assay 
  To further validate the TNF- inhibitors identified from 
both the homogenous HTRF-based and the AlphaLISA-
based TNF- assays, eight compounds were selected based 
on potency and diversity of mechanism of action and pur-
chased from commercial chemical vendors. The inhibitory 
effect of these compounds on LPS induced TNF- 
 
 
 
 
 
 
 
 
 
 
 
       A          B  
Fig. (4). (A) Time course of LPS-induced TNF- production. THP-1 cells were treated with various LPS concentrations for 5, 17 and 24 hr. 
At the end of various time points, TNF- production was measured in THP-1 cells using a homogenous HTRF-based TNF- assay. Data are 
from a single experiment performed in quadruplicate, representative of several experiments. (B) Optimization of cell density. THP-1 cells 
were dispensed at 2k, 3k and 4k per well. After incubated with LPS for 17 hr, TNF- production in the cells was measured. Data are from a 
single experiment performed in quadruplicate.  26    Current Chemical Genomics, 2011, Volume 5  Leister et al. 
Table 1.  Potency  (M, IC50) and Efficacy (% in Parenthesis) of 25 Cherry-Picked Compounds in HTRF-Based TNF- Assay,   
AlphaLISA-Based TNF- Assay, and Cell Viability Assay 
Compound Name  HTRF  AlphaLISA  Cytotoxicity 
Albuterol hemisulfate  1.27 ± 0.79 (83)  2.76 ± 1.16 (82)  Inactive 
(-)--Methylnorepinephrine  0.17 ± 0.02 (96)  0.12 ± 0.04 (118)  Inactive 
Bay 11-7082  1.22 ± 0.11 (103)  1.22 ± 0.33 (121)  7.30 ± 0.59 (107) 
Bay 11-7085  0.87 ± 0.16 (100)  0.74 ± 0.17 (107)  10.4 ± 2.53 (103) 
BTO-1  6.15 ± 0.57 (74)  2.96 ± 1.62 (101)  17.4 ± 2.82 (54) 
CCG-2046  2.59 ± 0.17 (93)  1.15 ± 0.38 (168)  12.9 ± 1.1 (80) 
Dobutamine hydrochloride  0.44 ± 0.04 (92)  0.51 ± 0.06 (104)  Inactive 
Ellipticine  4.06 ± 1.28 (108)  1.57 ± 0.41 (121)  14.5 ± 1.18 (110) 
(-)-Epinephrine bitartrate  0.05 ± 0.01 (96)  0.07 ± 0 (71)  Inactive 
(±)-Epinephrine hydrochloride  0.14 ± 0.01 (97)  0.15 ± 0.03 (121)  Inactive 
Fenoterol hydrobromide  0.12 ± 0.012 (96)  0.12 ± 0.057 (110)  Inactive 
Formoterol  0.004 ± 0.001 (88)  0.006 ±.0039 (90)  Inactive 
Histamine dihydrochloride  1.11 ± 0.401 (77)  1.89 ± 0.26 (61)  Inactive 
IRAK-1/4 Inhibitor I  2.68 ± 0.37 (88)  1.12 ± 0.06 (103)  Inactive 
(±)-Isoproterenol hydrochloride  0.016 ± 0.001 (93)  0.016 ± 0.003 (100)  Inactive 
Isotharine mesylate  1.83 ± 1.69 (103)  2.07 ± 0.93 (98)  Inactive 
L(-)-Norepinephrine bitartrate  0.12 ± 0.01 (88)  0.10 ± 0.03 (170)  Inactive 
Metaproterenol hemisulfate  0.52 ± 0.10 (91)  0.60 ± 0.10 (104)  Inactive 
N-p-Tosyl-L-phenylalanine chloromethyl ketone  2.64 ± 0.63 (94)  1.08 ± 0.26 (210)  29.1 ± 2.36 (125) 
Parthenolide  2.51 ± 0.28 (103)  1.30 ± 0.50 (120)  8.89 ± 2.84 (79) 
PD 169316  0.11 ± 0.04 (77)  0.14 ± 0.10 (91)  30.7 ± 0 (62) 
Ritodrine hydrochloride  2.52 ± 0.27 (71)  3.498 ± 0.73 (71)  Inactive 
S(+)-Isoproterenol(+)-bitartrate  0.056 ± 0.003 (96)  0.071 ± 0.004 (101)  Inactive 
Salbutamol  1.78 ± 1.42 (67)  3.34 ± 2.34 (77)  Inactive 
Terbutaline hemisulfate  2.88 ± 0.71 (103)  2.18 ± 1.02 (112)  Inactive 
Each value is the mean ± SD of the results from two experiments in duplicates. 
production in THP-1 cells was determined using a traditional 
ELISA assay that is the gold standard for cytokine measure-
ment. As shown in Table 2, all eight compounds inhibited 
LPS induced TNF- production with IC50s ranging from 10 
nM to 1.95 M. It was notable that the potencies of all the 
compounds tested in the ELISA-based assay were higher 
than the potencies obtained from the HTRF-based assay, 
with IC50 shifts ranging from 2- to 7-fold (Table 2). For ex-
ample, Bay 11-7085 had higher potency in the ELISA-based 
assay (IC50, 0.293 M) than in the HTRF-based assay (IC50, 
1.43 M), with a 4.9-fold IC50 shift (Fig. 5A). The IC50 shifts 
of CCG-2046 (2.32 M in the HTRF assay, and 0.66 M in 
the ELISA assay, Fig. 5B), IRAK-1/4 inhibitor I (2.76 M in 
HTRF assay, and 0.52 M in ELISA assay, Fig. 5C), and PD 
169316 (78.2 nM in HTRF assay, and 10.6 nM in ELISA 
assay, Fig. 5D) were 4-, 5- and 7-fold, respectively. The 
other four compounds, BTO-1, dobutamine, ellipticine and 
histamine, had 2 to 3-fold IC50 shifts (Table 2). However, the 
ranking orders of the compound potencies were comparable 
between the two assay formats. The IC50 values of these 
compounds in both the ELISA-based and HTRF-based as-
says correlated very well with an R
2 of 0.93. In addition, 
these eight compounds were also tested in a cell viability 
assay to evaluate the potential cytotoxicity because the cyto-
toxic compounds could show the false effect on the reduc-
tion of TNF- production in the cell based assays. We found 
that all these compounds showed none or weak cytotoxic 
effect (Table 2). Taken together, these data suggest that the 
homogenous HTRF-based TNF- assays can be used to 
identify small molecule compounds that inhibit TNF- pro-
duction. 
DISCUSSION 
  The measurements of cytokine levels in serum and tis-
sues are important to study the immune response, inflamma-
tory disease status and drug responses. Radioimmunoassay 
(RIA) was first developed to measure the concentration of 
insulin in plasma [18]. RIA is a sensitive in vitro method that 
is also applied to measure other antigen and cytokines. Homogeneous Cell-Based Human TNF- Assays  Current Chemical Genomics, 2011, Volume 5    27 
Table 2.  Comparison of Potency (M, IC50) of Commercial Ordered Compounds in ELISA-Based TNF-, HTRF-Based TNF-, 
and Cell Viability Assays 
Compound Name  ELISA  HTRF  Cytotoxicity 
Bay 11-7085  0.33 ± 0.15  1.45 ± 0.11  7.72  
BTO-1  1.95 ± 0.7  4.61 ± 0.37  12.9  
CCG-2046  0.64 ± 0.09  2.44 ± 0.002  8.66  
Dobutamine hydrochloride  0.09 ± 0.05  0.21 ± 0.02  Inactive 
Ellipticine  0.44 ± 0.07  1.38 ± 0.22  10.9 
Histamine dihydrochloride  0.71 ± 0.31  1.37 ± 0.003  Inactive 
IRAK-1/4 Inhibitor I  0.54 ± 0.1  3.14 ± 1.69  Inactive 
PD 169316  0.01 ± 0.001  0.07 ± 0.01  25.9 
Each value in ELISA and HTRF-based assays is the mean ± SD of the results from two experiments in duplicates. Cell viability assay was performed in duplicates from one experi-
ment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Concentration response curves of TNF- inhibitors in a HTRF-based TNF- assay () and ELISA-based assay (). TNF- level 
was measured after THP-1 cells were incubated with various concentrations of Bay 11-7085 (A), CCG-2046 (B), IRAK-1/4 inhibitor (C) and 
PD 169316 (D) in the presence of 1 g/ml LPS for 17 hr. 
Although this assay is sensitive and specific, it requires the 
use of radioisotope and thus produces the radioactive waste. 
The RIA assay involves a specific antibody that recognizes 
the radioactive labeled cytokine tracer and multiple assay 
steps including extensive wash cycles. In the 1970s, ELISA 
[19, 20], also known as an enzyme immunoassay (EIA), was 
introduced, where the specific antigen (cytokine)-antibody 
reaction was measured using colorimetric readout instead of 
a radioactive signal. In the ELISA method, two specific anti-
bodies are usually used with one antibody linked to a re-
porter enzyme. After several extensive reagent additions and 
plate washes, the substrate is added and a color change re-28    Current Chemical Genomics, 2011, Volume 5  Leister et al. 
sults from an enzyme reaction due to the binding of cytokine 
to enzyme linked antibody. The intensity of the color pro-
duced is proportional to the levels of the cytokine such as 
TNF-. The ELISA method is widely utilized in biomedical 
research because it doesn’t use radioactivity and is a standard 
method used in immunological experiments to detect cytoki-
nes.  
  For the large scale compound library screening, the 
throughput using ELISA is low and the assay procedure is 
complicated because the ELISA assay requires extensive 
wash cycles and antibody pre-coated plates. Therefore, the 
homogenous and simple assay method for measurement of 
cytokine level is needed for compound library screens. The 
assay should be miniaturized into high plate density formats 
such as 384-well and 1536-well plates as well as being sensi-
tive to compounds. We have optimized the HTRF-based and 
AlphaLISA-based TNF- assay into the homogenous format. 
The detection reagents are directly added into the wells of 
the assay plate treated with stimulant and compounds with-
out involving the medium transferring that is needed in the 
original assay protocol. We found that the activities of TNF-
 inhibitors identified in these homogenous assays were well 
correlated with those obtained from the ELISA-based assay. 
  Compared to the traditional ELISA method, these assays 
can be easily miniaturized into a 1536-well plate format and 
are homogeneous, and no plate wash or supernatant transfer 
steps. The frequent plate incubations needed in the ELISA 
assay was reduced significantly. Furthermore, the ratiometric 
readout from the dual emissions (665 and 615 nm) used in 
the HTRF-based TNF- assay minimizes the well-to-well 
and plate-to-plate variations that are caused by subtle differ-
ences in cell numbers and dispensing error. 
  We also found that the potencies of compounds obtained 
in the HTRF-based TNF- assay were slightly lower than 
those measured in the ELISA method. Among these com-
pounds tested, a 2- to 7-fold shift of activities was observed. 
This could be due to the fact that ELISA can have increased 
sensitivity because it is a plate based, and fixed assay system 
which increases the capture ability of the antibody. Also, the 
many wash steps in the ELISA protocol will remove any 
non-specific binding of the antibody. Finally, the antibodies 
used in the different assays may have different affinities for 
the antigen, resulting in different sensitivity of the assay. 
However, the potency ranking orders of compounds tested in 
ELISA and homogenous assay formats were similar. There-
fore, both the HTRF-based and AlphaLISA-based TNF- 
assays are still preferable for high throughput screening of 
large compound collection. The ELISA based TNF- assay 
can be used as a confirmation assay to validate the active 
compounds identified from the primary screens.  
  Beta-adrenergic agonists are known to suppress LPS-
induced TNF- production [21]. After a beta-adrenergic 
agonist binds to its receptor, adenylyl cyclase (AC) is acti-
vated by GS protein which leads to an increase of intracellu-
lar cAMP. It has been shown that the increased cAMP stimu-
lated by beta-adrenergic agonists can reduce the TNF- 
mRNA levels [22]. Consistent with previous reports, we 
found more than a dozen beta adrenergic agonists including 
norepinephrine, epinephrine, dobutamine and fenoterol from 
the LOPAC library with an inhibitory effect on TNF- pro-
duction. In addition, we also found that histamine inhibited 
LPS-induced TNF- production in THP-1 cells, which is 
consistent with a previous report that histamine suppressed 
the LPS-induced synthesis of TNF- in peripheral blood 
mononuclear cells [23]. The inhibition of histamine on TNF-
 production is caused by a similar mechanism as the beta 
adrenergic agonists. Histamine binds to and activates the 
histamine type 2 (H2) receptor that resulting in activation of 
GS protein, and AC and thus increasing intracellular cAMP 
[23].  
  The binding of TNF- to its receptor initiates the signal-
ing cascade resulting in activation of the NF-B and MAP 
kinase signaling pathways [7]. Previous studies reported that 
Bay 11-7082 [24], Bay 11-7085 [25], N-p-tosyl-L-
phenylalanine chloromethyl ketone [26], IRAK-1/4 inhibitor 
I [27], and parthenolide [28] had inhibitory effects on the 
NF-B signaling pathway. PD 169316 [29] was reported to 
inhibit the p38 MAP kinase. These compounds were found 
in our LOPAC library screen to inhibit the LPS induced 
TNF- production in THP-1 cells, suggesting that the inhibi-
tion of NF-B and MAP kinase signaling pathways by these 
compounds could be a result of the inhibition of TNF- pro-
duction.  
  BTO-1, CCG-2046, and ellipticine were identified as 
inhibitors of LPS induced TNF- production from this LO-
PAC library screen. BTO-1 is a polo-like kinase I inhibitor, 
which inhibits spindle assembly, mitotic entry and chromo-
some segregation [30]. Ellipticine, an alkaloid derived from 
the leaves of the evergreen tree, is known as a DNA interca-
lating agent [31] and an inhibitor of the enzyme topoi-
somerase II [32]. However, the roles of these compounds 
and the mechanism of action on LPS-induced TNF- produc-
tion still need further investigation. These compounds might 
be useful as research tools in the fields of inflammation and 
immunology.  
  In summary, we have optimized and validated two ho-
mogenous TNF- assays using HTRF and AlphaLISA assay 
formats. Both assays were miniaturized into 1536-well plates 
in a qHTS format. From a test screen of the LOPAC library, 
we have identified twenty-five TNF- inhibitors. All these 
compounds showed reproducible activities in these two as-
says. Eight out of the 25 compounds were further evaluated 
in the traditional ELISA based TNF- assay. The IC50 values 
of these compounds measured from the homogenous HTRF-
based TNF- assay correlated very well with those deter-
mined in the TNF- ELISA assay. Out of the 25 compounds, 
15 are beta adrenergic receptor agonists, five are known in-
hibitors of the NF-B pathway, and one compound is a his-
tamine H2 receptor agonist. The identification of these 21 
known inhibitors further demonstrated that these two ho-
mogenous TNF- assays reported here are valid for com-
pound screening. We also found four compounds including 
BTO-1, CCG-2046, ellipticine, and PD 169316 as new in-
hibitors of LPS induced TNF- production. Taken together, 
our results indicated that these homogenous TNF- assays 
can be used to quickly and efficiently screen large compound 
collections and to identify compounds that can potentially 
inhibit TNF- production.  
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